Single-Cell Polyfunctional Strength Applied to Checkpoint & Antibody Based Immunotherapies

Discover how polyfunctional strength is making an impact with bispecifics and combination checkpoint therapies

[wpbb post:title]
Will Singleterry, PhD, Director of Business Development, IsoPlexis
  • Evaluate T cell responses induced by various bispecific T cell engagers across phenotypes

  • Understand the heterogeneity of TIL polyfunctionality in solid tumors in response to checkpoint inhibitors

  • Uniquely correlate clinical anti-tumor responses with IsoPlexis data

2020-09-21T01:38:27-04:00